<DOC>
	<DOCNO>NCT00789256</DOCNO>
	<brief_summary>The purpose study determine response rate combination bortezomib melphalan patient Acute Myelogenous Leukemia ( AML ) high-risk Myelodysplastic Syndromes ( MDS ) .</brief_summary>
	<brief_title>Low Dose Melphalan Bortezomib AML High-Risk MDS</brief_title>
	<detailed_description>In patient develop acute myelogenous leukemia ( AML ) high-risk myelodysplastic syndrome ( MDS ) , current standard treatment involve multidrug induction chemotherapy utilize anthracycline anthraquinone cytarabine . While chemotherapy proven effective induce remission 90 % patient , elderly patient fair far bad . In patient age sixty , disease less responsive therapy , increase number comorbid condition make induction therapy dangerous endeavor . Because , many patient offer standard induction chemotherapy dearth viable alternative treatment otherwise fatal disease . Low dose melphalan previously show effective palliative treatment patient diagnose AML high-risk MDS . It find overall response rate 40 % AML patient ( 30 % complete remission 10 % partial remission ) 57 % overall response high-risk MDS patient ( 33 % complete remission , 5 % partial remission , 19 % minor response ) . This therapy , curative , one option patient unable tolerate intensive treatment regimen , desire potentially effective palliative regimen . Bortezomib ( VELCADEÂ® ) intravenously administer reversible , selective inhibitor 26S proteosome . Although mechanisms novel drug act antineoplastic agent fully understood , vivo vitro study indicate ultimately result inhibition gene expression necessary cell growth survival pathway , apoptotic pathway , cellular adhesion , migration , angiogenesis mechanism . Preclinical clinical evaluation combination melphalan bortezomib demonstrate impressive synergy refractory multiple myeloma cell line patient myeloma . This study aim determine finding hold true AML MDS patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Pathologic diagnosis AML highrisk MDS Patients chronic myelomonocytic leukemia refractory cytopenia multilineage dysplasia eligible one follow criterion : &gt; 4 unit red blood cell transfuse previous 3 month platelet count &lt; 50,000/uL absolute neutrophil count &lt; 1000/uL recent infection require antibiotic Patients may either consider poor candidate standard induction chemotherapy base reasonable medical evidence decline therapy , still desire palliative treatment beyond best supportive care Primary refractory disease disease relapse prior cytoxic therapy Karnofsky performance status &gt; 50 % Patients may receive prior growth factor therapy Patients receive prior therapy ( ex . melphalan , 5azacitidine , lowdose cytarabine ) control MDS AML prior registration ( Stratum 2 ) , clearly nonresponders eligible enrollment expect toxicity prior therapy resolve Voluntary write informed consent If female , subject either postmenopausal surgically sterilize willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study If male , subject agrees use acceptable method contraception duration study Patients previously treat eligible study : 1. previous therapy ineffective 2. expect toxicity previous treatment resolve 3 . In general follow guideline regard elapsed time previous treatment eligibility follow 1 . High intensity cytotoxic treatment ( 7 &amp; 3 induction , High Dose AraC ) : 4 week 2 . Hematopoeitic growth factor : delay require 3 . Low intensity treatment ( oral melphalan hydrea , low dose cytarabine 5azacitidine ) No delay require expect toxicity resolve regimen ineffective AML FAB M3 No concomitant malignancy curatively treat carcinoma situ cervix basal squamous cell carcinoma skin Active , uncontrolled infection Chronic liver disease due AML , bilirubin &gt; 2.0mg/dL End stage kidney disease dialysis Active CNS disease . A lumbar puncture prior treatment require perform absence significant CNS symptom sign Patient sensory peripheral neuropathy &gt; grade 2 painful peripheral neuropathy &gt; grade 1 ( see appendix A NCI sensory neuropathy toxicity criterion ) within 14 day enrollment Hypersensitivity bortezomib , boron mannitol Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum Bhuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman Serious medical psychiatric illness likely interfere participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>MDS</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
</DOC>